Drug intelligence / Profile preview

hinokitiol

Development stage
Preclinical
Modality
Small Molecules
Administration
Topical, Oral (supplement/nutraceutical), Intratracheal, Other Experimental/local
01

Overview

Hinokitiol is a naturally occurring **tropolone derivative** and monoterpenoid, most commonly isolated from the heartwood of several Cupressaceae (cypress family) trees[3][4]. It has **broad-spectrum antibacterial, antifungal, antioxidant, anti-inflammatory, anti-melanogenic**, and mild **antiviral properties**[3][4][5]. Mechanistically, hinokitiol acts primarily by chelating metal ions (notably iron and copper), which can disrupt metal-dependent bacterial enzymatic systems and generate reactive oxygen species[5][6][11]. It also inhibits NF-κB signaling, suppresses matrix metalloproteinases, and activates caspase-3, contributing to its anti-inflammatory and cytoprotective actions[4]. Hinokitiol is effective against both Gram-positive and Gram-negative bacteria (including methicillin-resistant *Staphylococcus aureus* and some antibiotic-resistant strains), reduces inflammation in dermatologic conditions, and inhibits efflux pumps in bacteria, thereby enhancing the efficacy of tetracycline and bismuth-based antibiotics[5][11]. It is used in some oral care and topical consumer hygiene products, and is investigated primarily as a **dietary supplement or cosmeceutical ingredient**, not as an approved pharmaceutical[4][5].

Other names
hinokitiolβ-thujaplicin2-hydroxy-4-isopropylcyclohepta-2,4,6-trien-1-oneThujaplicin
02

Targets

BEP (Bacterial efflux pump system)Bacterial iron-dependent enzymes and respiratory chain components

Beyond the preview

Go deeper on hinokitiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hinokitiol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call